Cannabinoids in bipolar affective disorder: A review and discussion of their therapeutic potential

Journal of Psychopharmacology

Volumn 19, Issue 3, 2005, Pages 293-300

  Ashton, C H ^a   Moore, P B ^a   Gallagher, P ^a   Young, A H ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Bipolar disorder; Cannabidiol; Cannabinoids; Cannabis; CBD; Depression; Dronabinol; Mania; Nabilone; Tetrahydrocannabinol; THC

Indexed keywords

11 HYDROXYTETRAHYDROCANNABINOL; 2 ARACHIDONOYLGLYCEROL; ANANDAMIDE; CANNABIDIOL; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABIS; DIAZEPAM; DRONABINOL; DRUG METABOLITE; HALOPERIDOL; NABILONE; PHENYTOIN; PLANT EXTRACT; TETRAHYDROCANNABINOL; TETRAHYDROCANNABINOL DERIVATIVE; UNCLASSIFIED DRUG;

ANTICONVULSANT ACTIVITY; ANTIDEPRESSANT ACTIVITY; ANTIPSYCHOTIC ACTIVITY; BIPOLAR DISORDER; CLINICAL TRIAL; DEPRESSION; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG RECEPTOR BINDING; HUMAN; HYPNOSIS; MANIA; NEUROPHARMACOLOGY; NONHUMAN; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SEDATION; TRANQUILIZING ACTIVITY;

ARACHIDONIC ACIDS; BIPOLAR DISORDER; CANNABIDIOL; CANNABINOIDS; HUMANS; POLYUNSATURATED ALKAMIDES; RECEPTOR, CANNABINOID, CB1; TETRAHYDROCANNABINOL;

EID: 18844381146     PISSN: 02698811     EISSN: None     Source Type: Journal    
DOI: 10.1177/0269881105051541     Document Type: Review

References (105)

1. 1- tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacol Rev 38: 21-43
2. Alger B E (2004) Endocannabinoids: getting the message across. Proc Natl Acad Sci 101: 8512-8513
3. Altshuler L L, Bartzokis G, Grieder T, Curran J, Jimenez T, Leight K, Wilkins J, Gemer R, Mintz J (2000) An MRI study of temporal lobe structures in men with bipolar disorder or schizophrenia. Biol Psychiatry 48: 147-162
4. Ameri A (1999) The effects of cannabinoids on the brain. Prog Neurobiol 58: 315-348
5. Arsenault L, Cannon M, Witton J, Murray R M (2004) Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiatry 184: 110-117
6. Ashton H (1999a) Cannabis in palliative care. CME Bull Palliat Med 1: 73-77
7. Ashton H (1999b) Adverse effects of cannabis and cannabinoids. Br J Anaesth 83: 637-649
8. Ashton H, Young A H (2003) GABA-ergic drugs: exit stage left, enter stage right. J Psychopharmacol 17: 174-178
9. 9-tetrahydrocannabinol in man. Br J Clin Pharmacol 12: 705-720
10. Bisogno T, Hanus L, De Petrocellis L, Tchilibon S, Ponde D, Brandi I, Moriello A S, Davis J B, Mechoulam R, Di Marzo V (2001) Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 134: 845-852
11. British Medical Association (1997) Therapeutic Uses of Cannabis. Harwood Publishers, London
12. Brown E, Suppes T, Adinoff B, Thomas NR (2001) Drug abuse and bipolar disorder: comorbidity or misdiagnosis? J Affect Dis 65: 105-115
13. Carlini E A, Cunha J M (1981) Hypnotic and antiepileptic effects of cannabidiol. J Clin Pharmacol 21: 417S-427S
14. Cassidy F, Ahearn E P, Carroll B J (2001) Substance abuse in bipolar disorder. Bipolar Disord 3: 181-188
15. Christie M J, Vaughan C W (2001) Cannabinoids act backwards. Nature 410: 527-30
16. Committee on Safety of Medicines (2003) Current Problems in Pharmacovigilance 29: 6
17. Consroe P, Sandyk R (1992) Potential role of cannabinoids for therapy of neurological disorders. In Murphy L, Bartke A (eds), Marijuana/ Cannabinoids: Neurobiology and Neuropsychology. CRC Press, Boca Raton, FL, pp. 459-524
18. Consroe P, Snyder S R (1986) Therapeutic potential of cannabinoids for therapy of neurological disorders. In Mechoulam R (ed.), Cannabinoids as Therapeutic Agents. CRC Press, Boca Raton, FL, pp. 21-49
19. Cunha J M, Carlini E A, Pereira A E, Ramos O L, Pimentel G, Gagliardi R, Sanvito E L, Lander N, Mechoulam R (1980) Chronic administration of CBD to healthy volunteers and epileptic patients. Pharmacologia 21: 175-185
20. Dalton E J, Cate-Carter T D, Mundo E, Parikh S V, Kennedy J L (2003) Suicide risk in bipolar patients: the role of co-morbid substance use disorders. Bipolar Disord 3: 58-61
21. Deadwyler S A, Hampson R E, Childers S R (1995) Functional significance of cannabinoid receptors in brain. In Pertwee R G (ed.), Cannabinoid Receptors. Academic Press Ltd, London, pp. 205-231
22. Di Marzo V, Goparaju S K, Wang L, Liu J, Batkai S, Jaral Z M, Fezza F, Miura G I, Palmiter R D, Sugiura T, Kunos G (2001) Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410: 822-825
23. Di Marzo V, Melck D, Brisogno T, De Petrocellos L (1998) Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci 21: 521-528
24. D'Souza D C, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu, Y, Braley G, Gueorguieva R, Krystal J H (2004) The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 29: 1558-1572
25. Drevets W C, Price J L, Simpson J R (1997) Subgenual prefrontal cortex abnormalities in mood disorders. Nature 386: 824-827
26. El-Badri S M, Ashton C H, Moore P B, Marsh V R, Ferrier I N (2001) Electrophysiological and cognitive function in young euthymic patients with bipolar affective disorder. Bipolar Disord 3: 79-87
27. Estroff T W, Dackis C A, Golod M S, Pottash A L C (1985) Drug abuse and bipolar disorders. Int J Psychiatry Med 15: 37-40
28. Ferrier I N, Thompson J M (2002) Cognitive impairment in bipolar affective disorder: implications for the bipolar diathesis. Br J Psychiatry 180: 293-295
29. Fabre L F, McLendon D (1981) The efficacy and safety of nabilone (a synthetic cannabinoid) in the treatment of anxiety. J Pharmacol Sci 21: 377S-382S
30. Gardner E L (1999) Cannabinoid interaction with reward systems. In Nahas G G, Sutin K M, Harvey D J, Agurell S (eds), Marihuana and Medicine. Humana Press, Totowa, New Jersey, pp. 187-205
31. Geddes J R, Carney S M, Davies C (2003) Relapse prevention with anti-depressant treatment in depressive disorders. Lancet 361: 643-651
32. Geddes J, Goodwin G (2001) Bipolar disorder: clinical uncertainty, evidence-based medicine and large-scale randomised trials. Br J Psychiatry 41 (Suppl): S191-S194
33. Gerth C W, Schultze-Lutter F, Mauss C, Ruhrmann S, Klosterkotter J, Leweke F M (2002) B113: the natural cannabinoid cannabidiol in the treatment of acute schizophrenia. Schizophr Res 53 (Suppl): 192
34. Gieringer D H (2003) The acceptance of medicinal marijuana in the US. J Cannabis Ther 3: 53-65
35. Glass R M, Uhlenhuth E H, Hartel F W, Schuster C R, Fischman M W (1980) A single dose study of nabilone, a synthetic cannabinoid. Psychopharmacology 71: 137-142
36. Gold M S (1992) Marihuana and hashish. In Winger G, Hoffman F G, Woods J H (eds). A Handbook of Drug and Alcohol Abuse. The Biological Aspects. Chapter 7. Oxford University Press, Oxford, pp. 117-131
37. Goodwin G M (2003) Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association of Psychopharmacology. J Psychopharmacol 17: 149-173
38. Goodwin G, Sachs G (2004) Definitions: Diagnosis and Comorbidity. Bipolar Disorder - Fast Facts. Health Press, Oxford
39. Grinspoon L, Bakalar J B (1998) The use of cannabis as a mood stabilizer in bipolar disorder: anecdotal evidence and the need for clinical research. J Psychoactive Drugs 30: 171-177
40. Grotenhermen F (2003) Clinical pharmacokinetics. J Cannabis Ther 3: 3-51
41. Gruber A J, Pope H G, Brown M E (1996) Do patients use marijuana as an antidepressant? Depression 4: 77-80
42. Guimaraes F S, Chiaretti T M, Graeff F G, Zuardi A W (1990) Antianxiety effect of cannabidiol in the elevated plus-maze. Psychopharmacology 100: 558-559
43. Herkenham M (1995) Localisation of cannabinoid receptors in brain and periphery. In Pertwee R G (ed.), Cannabinoid Receptors. Academic Press, London, pp. 145-166
44. Hodges C (1993) I wish I could get it at the chemist's. The Independent 23rd February 1993.
45. Howlett A C (1995) Cannabinoid compounds and signal transduction mechanisms. In Pertwee R G (ed.), Cannabinoid Receptors. Academic Press, London, pp. 167-204
46. Ilaria R L, Thornby J I, Fann W E (1981) Nabilone, a cannabinol derivative, in the treatment of anxiety neurosis. Curr Ther Res 29: 943-949
47. Johns A (2001) The psychiatric effects of cannabis. Br J Psychiatry 178: 116-122
48. Joy J E, Watson S J, Benson J A (eds) (1999) Marijuana and Medicine. National Academy Press, Washington, DC
49. Lloyd A J, Harrison C L, Ferner I N, Young A H (2003) The pharmacological treatment of bipolar affective disorder: practice is improving but could be better. J Psychopharmacol 17: 230-233
50. Macleod J, Oakes R, Copello A, Crome I, Egger M, Hickman M, Oppenkowski T, Stokes-Lampard H, Smith G D (2004) Psychological and social sequelae of cannabis and other illicit drug use by young people: a systematic review of longitudinal, general population studies. Lancet 363: 1579-1588
51. Marken P A, Stanislav S W, Lacombe S, Pierce C, Horstra R, Sommi R W (1992) Profile of a sample of subjects admitted to an acute care psychiatric facility with manic symptoms. Psychopharmacol Bull 28: 201-205
52. Martin B R, Cone E S (1999) Chemistry and pharmacology of cannabis. In Kalant H, Corrigal W A, Hall W, Smart R G (eds), The Health Effects of Cannabis. Centre for Addiction and Mental Health, Toronto, pp. 21-68
53. Martyn C N, Illis L S, Thom J (1995) Nabilone in the treatment of multiple sclerosis. Lancet 345: 579
54. Maykutt M O (1985) Health consequences of acute and chronic marihuana use. Prog Neuropsychopharmacol Biol Psychiatry 9: 209-238
55. McPartland J M, Russo E B (2001) Cannabis and cannabis extracts: greater than the sum of their parts? J Cannabis Ther 1: 103-32
56. Mechoulam R, Parker L A, Gallily R (2002) Cannabidiol: an overview of some pharmacological aspects. Clin Pharmacol 42: 11S-19S
57. Mendelson J H, Mello N K (1999) Marihuana effects on pituitary and gonadal hormones. In Nahas G G, Sutin K M, Harvey D, Agurell S (eds), Marihuana and Medicine. Humana Press, Totowa, NJ, pp. 385-392
58. Miller F T, Busch F, Tanenbaum J H (1989) Drug abuse in schizophrenia and bipolar disorder. Am J Drug Alcohol Abuse 15: 291-295
59. Mishra A, Moore P B, Hobbs R (2004) Does quetiapine have mood altering properties? J Psychopharmacol 18: 281-284
60. Monti J M (1997) Hypnotic-like effects of cannabidiol in the rat. Psychopharmacology 55: 263-265
61. Mueser K T, Yarnold P R, Bellack A S (1992) Diagnostic and demographic correlates of substance abuse in schizophrenia and major affective disorder. Acta Psychiatr Scand 85: 105-114
62. Musty R E, Reggio P, Consroe P (1995) A review of recent advances in cannabinoid research and the 1994 international symsposium on cannabis and the cannabinoids. Life Sci 56: 1933-1940
63. Negrete J C, Gill K (1999) Cannabis and schizophrenia: an overview of the evidence to day. In Nahas G G, Sutin K M, Harvey D, Agurell S (eds), Marihuana and Medicine. Humana Press, Totowa, NJ, pp. 671-682
64. Notcutt W, Price M, Chapman G (1997) Clinical experience with nabilone for chronic pain. Pharmaceutical Sci 3: 551-555
65. Paton WDM, Pertwee R G (1973) The actions of cannabis in man. In Nahas G G, Paton WDM (eds), Marijuana: Chemistry, Pharmacology, Metabolism and Clinical Effects. Pergamon Press, Oxford, pp. 735-38
66. 2 receptors. Pharmacol Ther 74: 129-180
67. Pertwee R G (1999a) Cannabinoid receptors and their ligands in brain and other tissues. In Nahas G G, Sutin K M, Harvey D, Agurell S (eds), Marihuana and Medicine. Humana Press, Totowa, NJ, pp. 177-185
68. Pertwee R G (1999b) Pharmacology of cannabinoid receptor ligands. Curr Med Chem 6: 635-664
69. Pertwee R G (2001) Cannabinoid receptors and pain. Prog Neurobiol 63: 569-611
70. Phillips M L, Drevets W C, Rauch S L, Lane R (2003) Neurobiology of emotion perception II: Implications for major psychiatric disorders. Biol Psychiatry 54: 515-528
71. Piomelli D, Giuffrida A, Calignano A, de Fonseca F R (2000) The endocannabinoid system as a target for therapeutic drugs. Trends Pharm Sci 21: 218-224
72. Porter R, Ferrier N, Ashton H (1999) Anticonvulsants as mood stabilisers. Adv Psychiatr Treat 5: 96-103
73. Randall R (ed.) (1991) Muscle Spasm, Pain and Marijuana Therapy. Galen Press, Washington, DC
74. Randall M D, Kendall D A (1998) Endocannabinoids: a new class of vasoactive substances. Trends Pharm Sci. 19: 55-58
75. Ratey J J, Ciraulo D A, Shader R I (1981) Lithium and marijuana. J Clin Psychopharmacol 1: 32-33
76. Regelson W, Butler J R, Schulz J, Kirk T, Peek L, Green M L, Zalis M O (1976) Delta-9-THC as an effective antidepressant and appetite-stimulating agent in advanced cancer patients. In Braude M C, Szara S (eds), The Pharmacology of Marihuana. Raven Press, New York, NY, pp. 763-776
77. Regier D A, Farmer M E, Rae D S, Locke B Z, Keith S J, Judd L L, Goodwin F K (1990) Comorbidity of mental disorders with alcohol and other drug abuse. J Am Med Assoc 264: 2511-2518
78. Rottanburg D, Robins A H, Ben-Arie O, Teggin A, Elk R (1982) Cannabis-associated psychosis with hypomanic features. Lancet 2: 1364-1366
79. Russo E (2003) Cannabis: from pariah to prescription. J Cannabis Ther 3: 1-29
80. Sachs G S, Printz D J, Kahn D A (2000) The Expert Consensus Guideline Series: Medication treatment of bipolar disorder. Postgrad Med Spec. No: 1-104
81. Shiloh R, Nutt D, Weizman A (1999) Atlas of Psychiatric Chemotherapy. Martin Dunitz, London
82. Solowij N (1998) Cannabis and Cognitive Function. Cambridge University Press, Cambridge
83. Sonne S C, Brady K T, Morton W A (1994) Substance abuse and bipolar affective disorder. J Nerv Ment Dis 182: 349-352
84. Steffens M, Feuerstein T J (2004) Receptor-independent depression of DA and 5-HT uptake by cannabinoids in rat neocortex-involvement of Na(+)/K(+)-ATPase. Neurochem Int 44: 529-538
85. Stein E A, Fuller S A, Edgemond W S, Campbell W B (1996) Physiological and behavioural effects of the endogenous cannabnoid, arachidonyl-ethanolamine (anandamide), in the rat. Br J Pharmacol 119: 107-114
86. Strakowski S M, DelBello M P, Sax K W (1999) Brain magnetic resonance imaging of structural abnormalities in bipolar disorder. Arch Gen Psychiatry 56: 254-260
87. Strakowski S M, DelBello M P, Fleck D E, Arndt S (2000) The impact of substance abuse on the course of bipolar disorder. Biol Psychiatry 48: 477-485
88. Sulcova E, Mechoulam R, Fride E (1998) Biphasic effects of anandamide. Pharmacol Biochem Behav 59: 347-353
89. Surguladze S, Keedwell P, Phillips M (2003) Neural systems underlying affective disorders. Adv Psychiatr Treat 9: 446-455
90. Svendsen K B, Jensen T S, Bach F W (2004) Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. Br Med J 329: 253-258
91. 1 cannabinoid receptors. Naunyn-Schmiedeberg's Arch Pharmacol 352: 576-579
92. 1 cannabinoid receptor antagonist, SR141716 A. Psychopharmacology 126: 165-172
93. Van der Stelt M, Di Marzo V (2003) The endocannabinoid system in the basal ganglia and in the meslolimbic reward system: implications for neurological and psychiatric disorders. Eur J Pharmacol 480: 133-150
94. Wade D, Robson P, House H, Makela P, Aram J (2003) A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehab 17: 18-26
95. Whittle B A, Guy G W, Robson P (2001) Prospects for new cannabis-based prescription medicines. J Cannabis Ther 1: 183-205
96. 1) receptors. Psychopharmacology 143: 315-317
97. Williamson E M, Evans F J (2000) Cannabinoids in clinical practice. Drugs 60: 1303-1314
98. Wilson R I, Nicol R A (2001) Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature 410: 558-559
99. Winokur G, Turvey C, Skiskal H, Coryell W, Solomon D, Leon A, Mueller T, Endicott J, Maser J, Keller M (1998) Alcoholism and drug abuse in three groups - bipolar I, unipolars and their acquaintances. J Affect Disord 50: 81-89
100. Wylie A S, Scott RTA, Burnett S J (1995) Psychosis due to 'skunk', Br Med J 311: 125
101. Zuardi A W, Guimaraes F S (1997) Cannabidiol as an anxiolytic and antipsychotic. In Mathre M L (ed.), Cannabis in Medical Practice. McFarland & Company, Jefferson, NC, pp. 133-141
102. 9-THC in normal subjects. Psychopharmacology 76: 245-259
103. Zuardi A W, Rodrigues J A, Cunha J M (1991) Effects of cannabidiol in animal models predictive of antipsychotic activity. Psychopharmacology 104: 260-264
104. Zuardi A W, Morais S L, Guimaraes F S, Mechoulam R (1995) Antipsychotic effect of cannabidiol. J Clin Psychiatry 56: 485-486
105. Zullino D F, Delessert D, Eap C B, Preisij M, Baumann P (2002) Tobacco and cannabis smoking cessation can lead to intoxication with clozapine or olanzapine. Int Clin Psychopharmacol 17: 141-143